<DOC>
	<DOCNO>NCT01801917</DOCNO>
	<brief_summary>This study ass efficacy , safety tolerability BAF312 administer orally patient clinically active polymyositis also patient polymyositis show inadequate response corticosteroid DMARDs ( disease modify antirheumatic drug ) .</brief_summary>
	<brief_title>Efficacy Tolerability BAF312 Patients With Polymyositis</brief_title>
	<detailed_description />
	<mesh_term>Polymyositis</mesh_term>
	<criteria>`` definite '' `` probable '' polymyositis least three month Baseline active disease define elevate CK level , enzymes , MRI/biopsy enzymes normal , persist muscle weakness stable dose corticosteroid least 2 week prior Baseline receive medium high dose last 8 week prior study entry . patient treated methotrexate must stable dose least 6 week prior Baseline . Patients overlap polymyositis , latestage polymyositis , type myositis . Preexisting severe cardiac pulmonary involvement , malignancy organ system significant eye disease . Uncontrolled diabetes mellitus diabetes complicate organ involvement . Pregnant nursing ( lactate ) woman Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Polymyositis , Myositis , PM</keyword>
</DOC>